Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 233

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon‐γ and interleukin‐17 production by human CD4+ T cells

Maeshima, Keisuke, Yamaoka, Kunihiro, Kubo, Satoshi, Nakano, Kazuhisa, Iwata, Shigeru, Saito, Kazuyoshi, Ohishi, Masanobu, Miyahara, Hisaaki, Tanaka, Shinya, Ishii, Koji, Yoshimatsu, Hironobu, Tanaka, Yoshiya·2012·Arthritis & Rheumatism

Abstract

Objective: Tofacitinib (CP‐690,550) is a novel JAK inhibitor that is currently in clinical trials for the treatment of rheumatoid arthritis (RA). The aim of this study was to examine the effects of tofacitinib in vitro and in vivo in RA, in order to elucidate the role of JAK in the disease process. Methods: CD4+ T cells, CD14+ monocytes, and synovial fibroblasts (SFs) were purified from the synovium and peripheral blood of patients with RA and were evaluated for the effect of tofacitinib on cytokine production and cell proliferation. For in vivo analysis, synovium and cartilage samples obtained from patients with RA were implanted in immunodeficient mice (SCID‐HuRAg mice), and tofacitinib was administered via an osmotic minipump. Results: Tofacitinib treatment of CD4+ T cells originating from synovium and peripheral blood inhibited the production of interleukin‐17 (IL‐17) and interferon‐γ (IFNγ) in a dose‐dependent manner, affecting both proliferation and transcription, but had no effect on IL‐6 and IL‐8 production. Tofacitinib did not affect IL‐6 and IL‐8 production by RASFs and CD14+ monocytes. However, conditioned medium from CD4+ T cells cultured with tofacitinib inhibited IL‐6 production by RASFs and IL‐8 production by CD14+ monocytes. Treatment of SCID‐HuRAg mice with tofacitinib decreased serum levels of human IL‐6 and IL‐8 and markedly suppressed invasion of synovial tissue into cartilage. Conclusion: Tofacitinib directly suppressed the production of IL‐17 and IFNγ and the proliferation of CD4+ T cells, resulting in inhibition of IL‐6 production by RASFs and IL‐8 production by CD14+ cells and decreased cartilage destruction. In CD4+ T cells, presumably Th1 and Th17 cells, JAK plays a crucial role in RA synovitis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.34329

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 233

Metadata

Authors
Maeshima, K., Yamaoka, K., Kubo, S., Nakano, K., Iwata, S., Saito, K., Ohishi, M., Miyahara, H., Tanaka, S., Ishii, K., Yoshimatsu, H., & Tanaka, Y.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2012-05-25
Volume
64
Issue
6
Pages
1790-1798
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2095522674
Cited by
233
References
3
FWCI
9.37
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon‐γ and interleukin‐17 production by human CD4+ T cells. https://app.cochat.ai/papers/10.1002/art.34329
The paper
Maeshima, K., Yamaoka, K., Kubo, S., Nakano, K., Iwata, S., Saito, K., Ohishi, M., Miyahara, H., Tanaka, S., Ishii, K., Yoshimatsu, H., & Tanaka, Y. (2012). The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon‐γ and interleukin‐17 production by human CD4+ T cells. Arthritis & Rheumatism. https://doi.org/10.1002/art.34329

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.